Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Short Interest Up 94.9% in July

Bayer Aktiengesellschaft (OTCMKTS:BAYRY – Get Free Report) was the recipient of a large growth in short interest in the month of July. As of July 31st, there was short interest totaling 522,716 shares, a growth of 94.9% from the July 15th total of 268,144 shares. Based on an average daily volume of 1,354,099 shares, the short-interest ratio is currently 0.4 days. Approximately 0.0% of the company’s shares are short sold.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on the stock. Zacks Research raised shares of Bayer Aktiengesellschaft from a “hold” rating to a “strong-buy” rating in a research report on Friday, July 10th. DZ Bank upgraded shares of Bayer Aktiengesellschaft from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, May 19th. Deutsche Bank Aktiengesellschaft raised shares of Bayer Aktiengesellschaft from a “hold” rating to a “buy” rating in a research note on Thursday, July 2nd. Finally, Jefferies Financial Group raised shares of Bayer Aktiengesellschaft to a “hold” rating in a research note on Friday, May 29th. Two equities research analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has issued a Hold rating to the company. According to MarketBeat, Bayer Aktiengesellschaft has an average rating of “Buy”.

Get Bayer Aktiengesellschaft alerts:

View Our Latest Stock Report on BAYRY

Bayer Aktiengesellschaft Price Performance

Shares of Bayer Aktiengesellschaft stock opened at $13.84 on Tuesday. The firm has a market cap of $54.39 billion, a price-to-earnings ratio of -27.14, a P/E/G ratio of 4.34 and a beta of 0.55. The stock has a 50-day simple moving average of $13.10 and a 200-day simple moving average of $12.16. Bayer Aktiengesellschaft has a 52-week low of $7.48 and a 52-week high of $15.23. The company has a debt-to-equity ratio of 1.06, a current ratio of 1.05 and a quick ratio of 0.70.

Bayer Aktiengesellschaft (OTCMKTS:BAYRY – Get Free Report) last released its quarterly earnings results on Tuesday, August 4th. The company reported $0.29 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.23 by $0.06. The company had revenue of $12.53 billion during the quarter, compared to the consensus estimate of $12.31 billion. Bayer Aktiengesellschaft had a positive return on equity of 17.00% and a negative net margin of 3.80%.Bayer Aktiengesellschaft has set its FY 2026 guidance at 1.200-1.346 EPS. On average, equities research analysts expect that Bayer Aktiengesellschaft will post 1.28 earnings per share for the current fiscal year.

Bayer Aktiengesellschaft Company Profile

(Get Free Report)

Bayer Aktiengesellschaft is a global life sciences company headquartered in Leverkusen, Germany, with a history dating back to 1863. The company operates across three principal business areas—Pharmaceuticals, Consumer Health and Crop Science—serving customers and markets worldwide. Bayer develops, manufactures and markets prescription medicines, over-the-counter healthcare products and agricultural solutions, and maintains research and development programs focused on new therapies and technologies in its core fields.

In Pharmaceuticals, Bayer focuses on prescription drugs across therapeutic areas such as cardiology, oncology, hematology and women’s health, supporting clinical development and regulatory activities for both marketed products and pipeline candidates.

See Also

• Five stocks we like better than Bayer Aktiengesellschaft
• Commodities Are Booming, But These 3 ETFs Tell Different Stories
• 3 Active ETFs Making Big Moves in August
• This ETF Is Outperforming by Avoiding the S&P 500’s Biggest Problem
• Birkenstock Beats the Skeptics—But Not on EPS

Receive News & Ratings for Bayer Aktiengesellschaft Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer Aktiengesellschaft and related companies with MarketBeat.com's FREE daily email newsletter.